EatonJ.S., MillerP.E., BentleyE., ThomasyS.M., and MurphyC.J.Slit lamp-based ocular scoring systems in toxicology and drug development: a literature survey. J. Ocul. Pharmacol. Ther., 33:707–717, 2017.
2.
EatonJ.S., MillerP.E., BentleyE., ThomasyS.M., and MurphyC.J.The SPOTS System: an ocular scoring system optimized for use in modern preclinical drug development and toxicology. J. Ocul. Pharmacol. Ther., 33:718–734, 2017.
3.
DraizeJ.H., WoodardG., and CalveryH.O.Methods for the study of irritation and toxicity of substances applied topically to the skin and mucous membranes. J. Pharmacol. Exp. Ther., 82:377–390, 1944.
4.
McDonaldT.O., and ShadduckJ.A.Eye irritation. In: MarzulliF.N., and MaibachH., eds. Advances in Modern Toxicology: Dermatoxicology and Pharmacology. New York: Hemisphere Publishing Corporation; 1977; p. 139–166.
5.
HackettR.B., and McDonaldT.O.Ophthalmic toxicology. In: MarzulliF.N., and MaibachH.I., eds. Dermatotoxicology. Washington, D.C.: Taylor & Francis; 1996; p. 299–306.
6.
CavetM.E., and DeCoryH.H.The role of nitric oxide in the intraocular pressure lowering efficacy of latanoprostene bunod: review of nonclinical studies. J. Ocul. Pharmacol. Ther., 34:52–60, 2017.
7.
LinC.W., ShermanB., MooreL.A., LaethemC.L., LuD.W., PattabiramanP.P., RaoP.V., deLongM.A., and KopczynskiC.C.Discovery and preclinical development of netarsudil, a novel ocular hypotensive agent for the treatment of glaucoma. J Ocul Pharmacol Ther. 34:40–51, 2017.
8.
BantseevV., EricksonR., LeipoldD., AmayaC., MillerP.E., BoolerH., ThackaberryE.A.Nonclinical safety assessment of anti-factor D: key strategies and challenges for the nonclinical development of intravitreal biologics. J. Ocul. Pharmacol. Ther., 34:203–213, 2017.
9.
JabsD.A., NussenblattR.B., and RosenbaumJ.T.Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am. J. Ophthalmol., 140:509–516, 2005.
